Consolidation of the Cosmetics and Regenerative Medicine Businesses under RMDC
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2024-Q1.
2 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「The Company resolved to transfer the Cosmetics Business operated by the Company and the Regenerative Medicine Business operated by 株式会社アルヌール to its wholly consolidated subsidiary 株式会社ＲＭＤＣ, and completed the business transfer effective 1 April 2023.」
The organizational restructuring effective 1 April 2023, consolidating the Cosmetics Business and アルヌール’s Regenerative Medicine Business under RMDC, was reaffirmed as the basis for changing the segment classifications in the current quarter. - FY2023First statedAnnual report
「At a meeting of the Board of Directors held on 30 March 2023, the Company resolved to transfer, effective 1 April 2023, the Cosmetics Business operated by the Company and the Regenerative Medicine Business operated by its wholly owned subsidiary 株式会社アルヌール to its wholly owned subsidiary 株式会社ＲＭＤＣ. The Company entered into a business transfer agreement on the same date and completed the business transfer on 1 April 2023.」
As part of an organizational restructuring to improve business efficiency, the Cosmetics Business and アルヌール’s Regenerative Medicine Business were consolidated under RMDC. The transfer price for the Cosmetics Business was stated as ¥92,848 thousand.